<p>LTS and any one else dealing with cancer, there is a magazizne my Dad gets:
[CURE:</a> Cancer Updates, Research & Education](<a href=“http://www.curetoday.com%5DCURE:”>http://www.curetoday.com) The subscription is free for people with cancer, check it out</p>
<p>It is for people dealing with cancer and is all about research and coping with Cancer. Here is one note in the latest magazine:</p>
<p>Erbitux Extends Lung Cancer Survival </p>
<p>One of the highlighted studies at this year’s meeting, the FLEX trial, showed Erbitux (cetuximab) extends overall survival by five weeks in non-small cell lung cancer—considered a success in this hard-to-treat cancer. </p>
<p>The international phase III study involved 1,125 newly diagnosed patients with latestage disease who were given either Erbitux plus chemotherapy (cisplatin and vinorelbine) or chemotherapy alone. While progressionfree survival remained unchanged between the two arms at 4.8 months, overall survival in the group receiving Erbitux and chemotherapy reached 11.3 months compared with 10.1 months in patients receiving only chemotherapy. One-year survival improved from 42 percent to 47 percent—a 5 percent absolute gain in survival. “To put it into perspective, that’s half the gain of adding chemotherapy to no treatment in the disease,” said Robert Pirker, MD, lead author of the study, at a press conference. </p>
<p>Dr. Pirker, of the Medical University of Vienna in Austria, suggested the study results could signal a change in the standard of care for metastatic lung cancer patients, possibly those ineligible for the targeted therapy Avastin (bevacizumab). Presented last year, Avastin combined with carboplatin and Taxol (paclitaxel) improved survival from 10.3 months with chemotherapy alone to 12.3 months. However, Dr. Pirker stressed that a direct comparison cannot be made from the two studies. </p>
<p>Side effects of Erbitux include neutropenia, anemia, and rash—a common effect in therapies that target the epidermal growth factor receptor, or EGFR. Studies have shown many lung cancer patients—as many as 80 percent—carry a mutated version of the EGFR gene. Erbitux is approved for colorectal cancer and head and neck cancer, and is expected to be submitted later this year for approval for newly diagnosed advanced lung cancer. —Elizabeth Whittington</p>